Oncopharmpod
HER3-DXd & Motixafortide
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:11:16
- More information
Informações:
Synopsis
An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).
